Spain Blood Glucose Monitoring Market Analysis
The Spain Blood Glucose Monitoring Market size is estimated at USD 517.13 million in 2025, and is expected to reach USD 799.33 million by 2030, at a CAGR of 9.1% during the forecast period (2025-2030).
In Spain According to WHO, as of 25 June 2022, a total of 102,258,825 vaccine doses have been administered. Regardless of previous diabetes history, admission hyperglycemia is a significant predictor of all-cause death in non-critically hospitalized COVID-19 patients. Spain was among the nations most severely impacted by the COVID-19 pandemic in 2020. A total countrywide lockdown was implemented from 14 March 2020 through 21 June 2020 to limit the epidemic due to an increase in instances.
The government reinstated a state of emergency on October 25 due to a return of cases after a nearly 4-month period during which certain restrictive measures had been lifted. This included partial lockdown measures with movement limitations that would extend until May 9 of 2021.
Critical elements of the therapy of type 1 diabetes include medical devices (T1D). Devices include insulin pumps, continuous glucose monitors (CGMs), and blood glucose meters. These gadgets are linked to better glucose management and decreased hypoglycemia.
Spain Blood Glucose Monitoring Market Trends
Increasing Type-1 diabetes population across Spain
Over the forecast period, the population of people with type 1 diabetes in Spain increased at a rate greater than 3%. In 2021, over 0.35 million people will live with type 1 diabetes. Diabetes is thought to affect up to 13.8% of adults in Spain, with approximately 6% having undiagnosed diabetes. Similar prevalence rates have been observed in Spain's five million-person Valencian Community. In this field, primary care physicians monitor most diabetic patients and work closely with endocrinologists to handle more complicated cases. Numerous studies have found that people with diabetes are more likely to have severe COVID-19 episodes, have poorer outcomes, and have a higher mortality rate. The SED expects the fatality rate to increase, as the mortality risk for the diabetic population in Spain is estimated to be around 7.3%, compared to 0.9%-3% for the non-diabetic population.
As a result of the factors above, the growth of the studied market in Spain is anticipated.
Continuous Glucose Monitoring Holds Highest CAGR in Spain Blood Glucose Monitoring Market.
The COVID-19 pandemic underscores the imperative of maintaining good glycemic control in patients with diabetes, as numerous observational studies have indicated that poorly managed diabetes is linked to an elevated risk of hospitalization and mortality from viral illnesses. The frequency of glucose level monitoring varies depending on the type of diabetes, which varies from patient to patient. Patients with Type-1 diabetes must regularly monitor their blood glucose levels to track their blood glucose levels and adjust insulin dosing accordingly. Modern CGM devices provide a comprehensive representation of blood glucose patterns and trends, in contrast to traditional glucose level checks at predetermined intervals. Additionally, contemporary continuous glucose monitoring devices can either retrospectively display blood glucose level trends by downloading data or provide a real-time depiction of glucose levels through receiver displays.
The use of CGM by Type-1 diabetic patients is much less as compared to Type-2 diabetic patients. However the expenditure of Type-1 diabetic patients on these devices is nearly double that of Type-2 diabetics. The newest CGM models, the Abbott Freestyle Libre and the Dexcom G6 overcame many technical barriers. However, high costs and uncertainties about their efficacy and necessity have kept CGM from being widely used by people with Type-2 diabetes. Continuous glucose monitoring devices are becoming cheaper with new technologies, like cell phone integration.
Spain Blood Glucose Monitoring Industry Overview
The blood glucose monitoring market is moderately fragmented, with few major manufacturers present in the market for CGM devices, and very high market competition in the SMBG market. The CGM devices market is dominated by a few major players, like Dexcom, Medtronic, Abbott, and Senseonics. The market for BGM devices comprises more generic players like Roche, LifeScan, Arkray, Ascensia, etc. Technological innovations in the recent past helped the companies to strengthen their market presence.
Spain Blood Glucose Monitoring Market Leaders
Roche
Abbott
Medtronics
Dexcom
LifeScan
- *Disclaimer: Major Players sorted in no particular order
Spain Blood Glucose Monitoring Market News
- February 2024: The Dexcom One+ system, which shares the same sensor as the company's G6 CGM, represents a significant advancement as it integrates the sensor from the G7 device, as stated in the company's launch announcement.
- March 2022: DexCom announced the receipt of CE Mark for its G7 CGM system in Europe, intended for people who have diabetes and are two years and older, including pregnant women. With this approval, the highly popular and best-selling real-time CGM in the world is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app.
- February 2021: Roche announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which supports and enables Roche's approach of integrated Personalised Diabetes Management (iPDM). Accu-Chek Instant features Bluetooth-enabled connectivity to the mySugr app, allowing wireless transfer of blood glucose results to the mySugr app.
